Better Health for All

Aethlon Medical's core product, the Hemopurifier, is a clinical-stage immunotherapeutic device designed to treat life-threatening conditions like cancer and viral infections, and for organ transplantation.

It holds FDA Breakthrough Device designations for two indications, demonstrating a transformative health impact. The company has a strong safety record, with human studies (164 sessions across 38 patients) reporting the device was used safely and well-tolerated, with only one non-serious Grade 2 adverse event (hemolysis and leaking filter) reported and resolved. The Hemopurifier targets vulnerable populations, including individuals with advanced or metastatic cancer unresponsive to standard care and those with life-threatening viruses lacking approved therapies, with an estimated 44 to 48 million people in the US affected by Long COVID alone. Aethlon Medical invested $2,212,000 in R&D in fiscal year 2025 and $2,520,000 in fiscal year 2024, with a substantial portion of its operating budget allocated to these activities. During the COVID-19 crisis, the company terminated its US and India-based studies due to low ICU patient volume and shifting priorities, despite the Hemopurifier being studied for severe SARS-CoV-2 infection. The company has received ethics committee approvals for clinical trials in Australia and India, with an independent Data Safety Monitoring Board providing recommendations. The company has provided training on its device to three hospitals in Australia. The company's annual report contains "forward-looking statements" and a "SUMMARY RISK FACTORS" section, indicating some disclosure but also highlighting a high degree of risk. Some of the company's patents may expire before FDA approval or approval in a foreign country is obtained.

Fair Money & Economic Opportunity

Aethlon Medical, Inc. is a medical technology company focused on developing therapeutic devices, such as the Hemopurifier, and is not a financial institution.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as the company's core business lies outside the scope of financial services.

Fair Pay & Worker Respect

The provided articles do not contain specific, quantitative data points for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce is not available.

While executive compensation and benefits upon termination are mentioned, these do not provide company-wide metrics for the relevant KPIs.

Honest & Fair Business

Aethlon Medical, Inc. corrected an accounting error during the fiscal year ended March 31, 2024, by reversing an incorrectly recorded accrued commission liability of approximately $404,000 that originated between 2017 and 2020.

Additionally, four out of five current directors on the company's Board of Directors meet the independence requirements of the Nasdaq Capital Market.

Kind to Animals

Aethlon Medical's contracts, active from September 2019 to September 2021, require research involving live vertebrate animals to conform with the Public Health Service Policy on Humane Care and Use of Laboratory Animals, including the Guide for the Care and Use of Laboratory Animals and USDA regulations.

The company has conducted animal studies in the past, with one article from 2005 noting the safe use of the Hemopurifier in animal studies for extended periods without adverse events. However, a more recent article from 2026 states that Aethlon is not currently conducting animal studies of its Hemopurifier cartridge. The company is conducting *in vitro* tests using human blood and *ex vivo* studies with human plasma to measure the Hemopurifier's effectiveness. Aethlon has relationships with three Biosafety Level 4 facilities, including the Centers for Disease Control and Prevention (CDC) and USAMRIID.

No War, No Weapons

Aethlon Medical is developing a therapeutic device under a DARPA contract, intended to reduce sepsis in combat-injured soldiers.

This indicates an emphasis on civilian medical applications, with military use being incidental. The company is subject to FAR Clause 52.204-25, which prohibits contracting for certain telecommunications and video surveillance services or equipment from specific companies, but there is no evidence of the company's own involvement in intelligence or surveillance activities.

Safe & Smart Tech

The company is required to comply with several regulations for its National Cancer Institute contract, including Section 508 of the Rehabilitation Act of 1973, 45 CFR Part 94, and specific FAR Clauses (52.204-21 and 52.204-25).

A December 2025 filing states compliance with the Sarbanes-Oxley Act of 2002, the Foreign Corrupt Practices Act of 1977, and the Currency and Foreign Transactions Reporting Act of 1970. The company regained compliance with Nasdaq Listing Rule 5550(a)(2) on June 25, 2025, after receiving a notice of non-compliance in June 2024 and an extension in January 2025. Additionally, the company received Indian regulatory approval (CDSCO) for an oncology study on June 19, 2025.

Zero Waste & Sustainable Products

Aethlon Medical's research and development activities involve the controlled use of hazardous materials, including chemicals for Hemopurifier cartridges and infected plasma samples for preclinical testing.

The company adheres to federal, state, local, and foreign laws governing the use, manufacture, storage, handling, and disposal of such materials. Direct costs of environmental compliance were immaterial for the fiscal year ended March 31, 2025, indicating no significant waste disposal violations during that period. The core Hemopurifier product is a single-use cartridge, which, after patient exposure, is classified as regulated medical waste (RMW).